(R)-4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-1-benzylpiperazin-2-one | 1314097-15-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (R)-4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-1-benzylpiperazin-2-one
• 英文别名: 4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1-benzylpiperazin-2-one
• CAS: 1314097-15-8
• 化学式: C₂₁H₂₂F₃N₃O₂
• 分子量: 405.42
• InChiKey: NZYAICYOZPCDLX-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 盐酸 、 甲醇 作用下， 以 1,4-二氧六环 为溶剂， 生成 (R)-4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-1-benzylpiperazin-2-one
  参考文献：
  名称：

  Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  摘要：

  A series of beta-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.029

文献信息

• Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
  作者：Heung Jae Kim、Woo Young Kwak、Jong Pil Min、Jae Young Lee、Tae Hyun Yoon、Ha Dong Kim、Chang Yell Shin、Mi Kyung Kim、Song Hyen Choi、Hae Sun Kim、Eun Kyoung Yang、Ye Hwang Cheong、Yu Na Chae、Kyung Jin Park、Ji Myun Jang、Soo Jung Choi、Moon Ho Son、Soon Hoe Kim、Moohi Yoo、Bong Jin Lee

  DOI：10.1016/j.bmcl.2011.04.029

  日期：2011.6

  A series of beta-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.